onc brain

The longer read

The headline EFS hazard ratio of 0.38 is large, but the endpoint's components decide how far it can carry. EFS here is the first of biochemical failure, locoregional recurrence, distant metastasis or death. In a post-prostatectomy population, biochemical failure will dominate that composite, and the trial's own testosterone data show why that matters: recovery to 200 ng/dL took a median of 20.7 months, roughly nine months after treatment ended. A meaningful part of the follow-up therefore measured PSA in men who were still functionally castrate. A PSA endpoint read under residual androgen suppression measures exposure to therapy as much as disease biology, and an EFS separation of this size is what one would expect from that mechanism alone, whether or not the underlying disease course changed.

The secondary endpoints were meant to answer that, and they only partly do. Time to first subsequent therapy (medians 46.0 vs 12.3 months) is vulnerable to the same problem, and the discussant estimated about 20 months of lead-time bias. MFS is the endpoint that could show durable benefit, and its hazard ratio of 0.49 has a wide interval (0.26-0.90) and a nominal p-value. The detection table also matters: most metastatic events were found on PSMA PET (9 vs 50 events), in a trial that staged its population with CT and bone scan alone. Van As's point is that an event called new metastasis may be disease that was present at baseline and only found later. Detection timing could differ between arms if hormonal therapy temporarily suppressed PSMA-avid disease, so the MFS difference may reflect when disease was found rather than whether it developed.

The population is also behind current staging. EAU and ESMO now advise PSMA PET for high-risk disease where available, and proPSMA's accuracy figures (92% vs 65%) suggest some enrolled men had occult nodal or distant disease. In a PSMA-staged population the absolute benefit could plausibly be smaller, because the men most likely to have early events would be identified and treated differently from the start.

Two design features limit the comparison further. The 1:3 allocation leaves 102 men in the experimental arm, which makes the secondary endpoints fragile. The control arm received adjuvant local or systemic treatment at the physician's discretion, so the comparator is not one defined strategy, and the source does not say how much adjuvant or salvage RT the control arm received.

What would change the read is maturation of MFS to a non-nominal result, ideally with OS, and some evidence that the effect holds once testosterone has fully recovered. Until then, this trial shows that perioperative apalutamide plus ADT delays PSA-defined events after prostatectomy. It does not yet show that it changes the metastatic course of the disease.